Exploring the impact of chronic obstructive pulmonary disease (COPD) on diabetes control in diabetes patients: a prospective observational study in general practice

Hilde D Luijks¹, Wim JC de Grauw¹, Jacobus HJ Bor¹, Chris van Weel¹², Antoine LM Lagro-Janssen¹, Marion CJ Biemans¹ and Tjard R Schermer¹

**BACKGROUND:** Little is known about the association between COPD and diabetes control parameters.

**AIMS:** To explore the association between comorbid COPD and longitudinal glycaemic control (HbA₁c) and systolic blood pressure (SBP) in a primary care cohort of diabetes patients.

**METHODS:** This is a prospective cohort study of type 2 diabetes patients in the Netherlands. In a mixed model analysis, we tested differences in the 5-year longitudinal development of HbA₁c and SBP according to COPD comorbidity (present/absent). We corrected for relevant covariates. In subgroup effect analyses, we tested whether potential differences between diabetes patients with/without COPD were modified by age, sex, socio-economic status (SES) and body mass index (BMI).

**RESULTS:** We analysed 610 diabetes patients. A total of 63 patients (10.3%) had comorbid COPD. The presence of COPD was not significantly associated with the longitudinal development of HbA₁c (P = 0.54) or SBP (P = 0.33), but subgroup effect analyses showed significant effect modification by SES (P < 0.01) and BMI (P = 0.03) on SBP. Diabetes patients without COPD had a flat SBP trend over time, with higher values in patients with a high BMI. For diabetes patients with COPD, SBP gradually increased over time in the middle- and high-SES groups, and it decreased over time in those in the low-SES group.

**CONCLUSIONS:** The longitudinal development of HbA₁c was not significantly associated with comorbid COPD in diabetes patients. The course of SBP in diabetes patients with COPD is significantly associated with SES (not BMI) in contrast to those without COPD. Comorbid COPD was associated with longitudinal diabetes control parameters, but it has complex interactions with other patient characteristics. Further research is needed.

**INTRODUCTION**

Chronic obstructive pulmonary disease (COPD) is typically diagnosed in middle-aged subjects who also have an increased risk for other chronic conditions.¹ The presence of other diseases in addition to an ‘index disease’ is defined as comorbidity.² Among patients with mild-to-moderate COPD, the main causes of death are comorbid diseases such as lung cancer and cardiovascular diseases.³ COPD has a large impact on morbidity and mortality.⁴

Another example of a chronic disease with marked effects on global health and health care is type 2 diabetes.⁵ Of all patients with COPD, 9–13% of the patients have comorbid diabetes,⁶⁻⁷ and 4–13% of patients with diabetes have comorbid COPD.⁹⁻¹¹ Although these numbers originate from different studies and consequently are not directly comparable, they clearly illustrate that the combination of COPD and diabetes is a rather common one.

In recent years, knowledge and awareness of the importance of patient-specific factors in the treatment of COPD¹² and diabetes¹³ has grown, resulting in an increased tendency to individualise disease management. An important characteristic of a patient with a specific chronic disease, such as COPD, is the comorbidity that may also be present. However, current guidelines for COPD and diabetes have limited applicability for patients with comorbid conditions.¹⁴ Very little is known on how the presence of a specific disease, such as COPD, influences the long-term outcomes of another disease, such as diabetes. This type of information is important if health care professionals aim to personalise disease management plans for COPD and diabetes patients. In addition, other characteristics such as age, sex, body mass index (BMI) and socio-economic status (SES) may have well-known effects on COPD¹⁵⁻¹⁷ and on diabetes,¹⁸⁻¹⁹ but how they interact if both diseases are present in one and the same patient is unknown. Detailed data on comorbidity, patient characteristics and disease control parameters from a representative patient population may inform us about the interaction between the two diseases and the impact on patients’ prognosis.

The aim of this explorative, hypothesis-generating paper was to investigate the association between COPD as a comorbid condition and longitudinal diabetes control parameters in patients with type 2 diabetes in primary care. We also explored the role of sex, age, BMI and SES in the relationship between COPD and diabetes control.

**MATERIALS AND METHODS**

Design and study subjects

We used available data from a dynamic prospective cohort of diabetes patients registered in the Continuous Morbidity Registration (CMR), a
beginning with either the start of the study period or the date of a
the observation period of the study (1 January 1985 to 31 December 2006).
from the CMR) on the course of diabetes control over time (data from the
two databases to study the effects of chronic comorbidity (data originating
composition of our diabetes cohort are described elsewhere.10 In short, we
have access to specialist care through that practice. In this system, where
data (e.g., HbA1C, glucose levels). Monitoring data are collected by the GPs
and/or hypertension. The NMP database includes demographic data,
record diagnostic and monitoring measurements of patients with diabetes
Netherlands,21 where patients are registered with a general practice and
Nijmegen region, the
general practice registration network in the Nijmegen region, the
Netherlands. The four practices constituting the CMR have been recording
practice. The observation period ended
s enrolment in a CMR practice. The observation period ended
either at the end of our study period or with a patient
deregistration from the practice. All four CMR practices also participate in the so-called
Nijmegen Monitoring Project (NMP),23 which was initiated in 1985 to systematically record
diagnostic and monitoring measurements of patients with diabetes
and/or hypertension. The NMP database includes demographic data,
physical diagnostics (e.g., blood pressure, weight, height) and laboratory
data (e.g., HbA1C, glucose levels). Monitoring data are collected by the GPs
and practice nurses during routine 3-monthly diabetes check-up visits for
all diabetes patients under GP care. The practices involved have been shown to provide good-quality diabetes care.22 We linked data from these
two databases to study the effects of chronic comorbidity (data originating
from the CMR) on the course of diabetes control over time (data from the
NMP). The current paper presents results from the effect of COPD, as
selected comorbid disease, on longitudinal diabetes control parameters,
and effect modification by a number of patient characteristics in subgroup
effect analyses. This analysis is part of a larger project studying the effects
of different types of comorbid diseases on diabetes control parameters.
The CMR and NMP registries comply with the Code of Conduct for
Health Research, which has been approved by the Data Protection
Authorities for conformity with the applicable Dutch privacy legislation. For
this study, approval of an ethics committee was not required.

Selection of COPD and other comorbidities
The presence of COPD was identified as a doctor diagnosis recorded in the
CMR database. The CMR has previously been used to study cohorts of patients with COPD,23,24 and the diagnoses correlate well with spirometry results.25 Details on the recording of comorbidity have been reported in a
previous paper.10 We selected comorbid COPD as a single disease of
particular interest for the analysis of possible associations between
comorbidity conditions and the course of diabetes control parameters, and
we were, in addition, interested especially in comorbid malignancies and
cardiovascular, mental and musculoskeletal diseases.

Study outcomes
HbA1C (in %, the current unit during our study period) and systolic blood
pressure (SBP, in mmHg) were the primary study outcomes. Measurement
of HbA1C is performed at the annual check-up visits. Blood pressure
measurement is generally performed at every check-up visit. To include
patients with sufficient follow-up starting from the diagnosis, we only
included patients with their first measurement performed within the first
4 months after the diabetes diagnosis and labelled these as ‘baseline
measurements’. All subsequent measurements were regarded as repeated
measurements for individual patients and contributed to the longitudinal
analysis. We studied the development of these outcomes during the 5-year
follow-up.

Statistical analysis
SPSS (version 20.0) and SAS (version 9.02) software supported the analysis.
Characteristics of the study population are provided using descriptive
statistics. We compared linear trends for both HbA1C and SBP in the 5 years
after the diabetes diagnosis between patients with and without
comorbid COPD. We applied a random intercept mixed model analysis
using measurements nested within patients.26 In this model, the presence
of existing COPD, i.e., recorded before the diabetes diagnosis, was the
variable of interest. We added an interaction term ‘time’ by ‘COPD’ (absent/
present) to the model to explore differences in HbA1C and SBP trends
according to the absence or presence of COPD. In this comparison between patients with and without COPD, we entered sex, age at diabetes
diagnosis, SES, BMI (handled as ‘last observation carried forward’26) and the
presence of other comorbidities (as specified above) as potential
confounders. Values for age and BMI were handled as continuous variables
in the final model, but we categorised them as ‘low’, ‘intermediate’ and ‘high’ values to facilitate (graphical) presentation of the results. The
categorisation was based on the limits of the first, second (i.e., the median)
and third quartiles of the distribution of age and BMI values of the patients
who contributed to the analysis.

Furthermore, we performed subgroup effect analyses to test whether
differential differences in the HbA1C and SBP trends between diabetes
patients with or without comorbid COPD were modified by sex, age, SES or
BMI. The confounders in the initial analysis were now tested for potential
effect modification separately by adding an interaction term ‘time’ by
‘COPD’ (absent/present) by ‘potential effect modifier’ to the model.
Nonsignificant interaction terms were removed in a stepwise backward
elimination procedure.26 In these subgroup effect analyses, we added the
presence of other comorbidities as potential confounders (not as potential
effect modifiers). In cases in which no significant results arose from the
subgroup effect analysis, the first model (without subgroup effect analysis)
defined the results.

Not only comorbid COPD already present at the study start may be
associated with the longitudinal diabetes outcomes, the same may be the
case for incident COPD after the patient’s diabetes diagnosis. Therefore, we
performed sensitivity analyses excluding the patients who did not have
COPD at their diabetes diagnosis date but who were diagnosed with COPD
during the 5-year follow-up.

A P-value < 0.05 was considered statistically significant.
Information for the de
the additional effects of covariates. The
time trends for patients with and without comorbid COPD and

After correction for covariates, comorbid COPD was not signi-
cantly associated with the course of HbA1C (P = 0.54) or SBP
(P = 0.33) values over time in the initial analyses. Figure 2 shows
the time trends for patients with and without comorbid COPD and
the additional effects of covariates. The figure footnotes provide
information for the definition of the ‘reference category’.
In the subgroup effect analyses, however, we found a
statistically significant association between comorbid COPD and
the course of SBP, with effect modification of SES (P < 0.01)
and BMI (P = 0.03). To express these complex findings in a
comprehensible way, Figure 3 shows a graphical representation of
the direction of effects, with separate graphs for combinations of
SES and BMI. The figure shows that in the absence of COPD (blue
lines), longitudinal SBP values are relatively stable over time, with
higher values when BMI is higher (compare panels a, c, and e).
Diabetes patients with comorbid COPD (red lines) showed a more
variable course of SBP over time, with SES more than BMI defining
the direction of effects and absolute SBP values. Note that, in the
subgroup effect analysis, nonsignificant terms were removed from
the model; i.e., all variables presented contributed significantly to
the model predicting the outcome. Age (P < 0.01), presence of
comorbid mental (P = 0.03) and comorbid cardiovascular disease
(P < 0.01) had additional effects on the subgroup effect analysis
results (not dependent on the presence or absence of comorbid
COPD, additional effects). Absolute values depended on the mix of
patient characteristics. No signi-
cant effect modification was
found from any of the defined subgroups on the longitudinal
development of HbA1C in the presence of comorbid COPD.

Sensitivity analysis
After exclusion of cases with incident COPD during the 5-year
follow-up period, we did not observe a significantly different
association between COPD and HbA1C (P = 0.54) or SBP (P = 0.34),
nor did we observe significant differences in the results from the
subgroup effect analyses.

RESULTS
Study subjects and baseline characteristics
Figure 1 shows a flowchart of our study population. We included
610 patients with a mean age of 63 years (s.d. 12.5, Table 1) for
longitudinal analysis. In all, 63 patients (10.3%) had comorbid
COPD at the date of their diabetes diagnosis, and another 8
patients were diagnosed with COPD during the 5-year follow-up
period. Patients with pre-existing COPD were older and had more
additional comorbid conditions, apart from COPD, compared with
patients without COPD (i.e., musculoskeletal disease, 51 vs. 30%).
Note that in the longitudinal analyses we corrected for the
presence of selected comorbidity.

Influence of comorbid COPD on the course of HbA1C and SBP
After correction for covariates, comorbid COPD was not signifi-
cantly associated with the course of HbA1C (P = 0.54) or SBP
(P = 0.33) values over time in the initial analyses. Figure 2 shows
the time trends for patients with and without comorbid COPD and
the additional effects of covariates. The figure footnotes provide
information for the definition of the ‘reference category’.
In the subgroup effect analyses, however, we found a
statistically significant association between comorbid COPD and
the course of SBP, with effect modification of SES (P < 0.01)
and BMI (P = 0.03). To express these complex findings in a
comprehensible way, Figure 3 shows a graphical representation of
the direction of effects, with separate graphs for combinations of
SES and BMI. The figure shows that in the absence of COPD (blue
lines), longitudinal SBP values are relatively stable over time, with
higher values when BMI is higher (compare panels a, c, and e).
Diabetes patients with comorbid COPD (red lines) showed a more
variable course of SBP over time, with SES more than BMI defining
the direction of effects and absolute SBP values. Note that, in the
subgroup effect analysis, nonsignificant terms were removed from
the model; i.e., all variables presented contributed significantly to
the model predicting the outcome. Age (P < 0.01), presence of
comorbid mental (P = 0.03) and comorbid cardiovascular disease
(P < 0.01) had additional effects on the subgroup effect analysis
results (not dependent on the presence or absence of comorbid
COPD, additional effects). Absolute values depended on the mix of
patient characteristics. No significant effect modification was
found from any of the defined subgroups on the longitudinal
development of HbA1C in the presence of comorbid COPD.

Sensitivity analysis
After exclusion of cases with incident COPD during the 5-year
follow-up period, we did not observe a significantly different
association between COPD and HbA1C (P = 0.54) or SBP (P = 0.34),
nor did we observe significant differences in the results from the
subgroup effect analyses.


Table 1. Baseline characteristics of patient population, according to the presence/absence of COPD

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total included n = 610</th>
<th>COPD present* n = 63</th>
<th>COPD absent* n = 547</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex: male, n (%)</td>
<td>294 (48.2)</td>
<td>34 (54.0)</td>
<td>260 (47.5)</td>
<td>0.33</td>
</tr>
<tr>
<td>Age at DM diagnosis, years; mean (s.d.)</td>
<td>63.0 (12.3)</td>
<td>69.0 (11.0)</td>
<td>62.3 (12.5)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Follow-up time, years; mean (s.d., range)</td>
<td>6.2 (4.6; 0.1–21.9)</td>
<td>4.1 (3.6; 0.3–15.6)</td>
<td>6.5 (4.7; 0.1–21.9)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Measurements per patient, total number, mean (median; s.d.; range)</td>
<td>21.8 (17.5; 18.2; 1–106)</td>
<td>15.7 (10.1; 14.9; 1–86)</td>
<td>22.5 (19.1; 18.4; 1–106)</td>
<td>0.001</td>
</tr>
<tr>
<td>BMI at baselineb, mean (s.d.), kg/m²</td>
<td>29.8 (5.1)</td>
<td>29.5 (5.2)</td>
<td>29.8 (5.1)</td>
<td>0.57</td>
</tr>
<tr>
<td>SESb, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>315 (52.1)</td>
<td>37 (58.7)</td>
<td>278 (51.3)</td>
<td>0.26</td>
</tr>
<tr>
<td>Middle</td>
<td>242 (40.0)</td>
<td>24 (38.1)</td>
<td>218 (40.2)</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>48 (7.9)</td>
<td>2 (3.2)</td>
<td>46 (8.5)</td>
<td></td>
</tr>
<tr>
<td>Year of diabetes diagnosis, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1985–1989</td>
<td>83 (13.6)</td>
<td>3 (4.8)</td>
<td>80 (14.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>1990–1999</td>
<td>235 (38.5)</td>
<td>24 (38.1)</td>
<td>211 (38.6)</td>
<td></td>
</tr>
<tr>
<td>2000–2006</td>
<td>292 (47.9)</td>
<td>36 (57.1)</td>
<td>256 (46.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Comorbidity data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comorbid diseasesc, present, n (%)</td>
<td>2.7 (2.3; 0–11)</td>
<td>4.0 (2.5; 0–11)</td>
<td>2.6 (2.2; 0–11)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Comorbid diseasesd, (categorised), n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>100 (16.4)</td>
<td>4 (6.3)</td>
<td>96 (17.6)</td>
<td>0.002</td>
</tr>
<tr>
<td>1 or 2</td>
<td>227 (37.2)</td>
<td>17 (27.0)</td>
<td>210 (38.4)</td>
<td></td>
</tr>
<tr>
<td>3 and more</td>
<td>283 (46.4)</td>
<td>42 (66.7)</td>
<td>241 (44.1)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular comorbiditye, present, n (%)</td>
<td>390 (63.9)</td>
<td>44 (69.8)</td>
<td>346 (63.3)</td>
<td>0.30</td>
</tr>
<tr>
<td>Musculoskeletal comorbidityf, present, n (%)</td>
<td>197 (32.3)</td>
<td>32 (50.8)</td>
<td>165 (30.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Mental comorbidityg, present, n (%)</td>
<td>140 (23.0)</td>
<td>18 (28.6)</td>
<td>122 (22.3)</td>
<td>0.26</td>
</tr>
<tr>
<td>Comorbid malignancyh, present, n (%)</td>
<td>42 (6.9)</td>
<td>4 (6.3)</td>
<td>38 (6.9)</td>
<td>0.86</td>
</tr>
<tr>
<td>Incident comorbid COPD after DM diagnosisi, n (%)</td>
<td>12 (2.0)</td>
<td>NA</td>
<td>12 (2.2)</td>
<td>NA</td>
</tr>
<tr>
<td>Incident COPD in the first year after DM diagnosis, n (%)</td>
<td>1 (0.2)</td>
<td>NA</td>
<td>1 (0.2)</td>
<td>NA</td>
</tr>
<tr>
<td>Incident COPD in the first 5 years after DM diagnosis, n (%)</td>
<td>8 (1.3)</td>
<td>NA</td>
<td>8 (1.5)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Characteristics of patients at baseline, i.e., at the date of the diabetes diagnosis.
Abbreviations: BMI, body mass index; DM, type 2 diabetes mellitus; NA, not applicable; SES, socio-economic status.
*Comorbid presence/absence: assessed on the date of diabetes diagnosis. P-values displayed are calculated for the difference between the group with versus
without comorbid COPD. We performed Chi-square tests for continuous variables and independent t-tests for continuous variables. P-values < 0.05 were
considered statistically significant.
†Number of measurements available for BMI at baseline: 576 (missing at baseline: n = 34). Number of measurements available for SES at baseline: 605 (missing
at baseline: n = 5).
‡Presence of any type of comorbid disease was assessed at the date of diabetes diagnosis. For the diabetes patients with comorbid COPD present at the
diabetes diagnosis date, we excluded COPD in the count of the total number of comorbid diseases to make a meaningful comparison with the total number of
comorbid diseases in patients without COPD.
§Mean time (after the diabetes diagnosis date) until the date of comorbid COPD diagnosis, for incident cases, is 4.6 years.

Impact of comorbid COPD on diabetes control
HD Luijks et al
4

Additional effects on course of HbA1C (Panel a):

<table>
<thead>
<tr>
<th>Variable</th>
<th>Effect on HbA1C (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>+0.04</td>
<td>0.70</td>
</tr>
<tr>
<td>Middle SES</td>
<td>-0.08</td>
<td>0.77</td>
</tr>
<tr>
<td>High SES</td>
<td>-0.05</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Low BMI</td>
<td>+0.09</td>
<td>0.08</td>
</tr>
<tr>
<td>Young age</td>
<td>-0.07</td>
<td>0.07</td>
</tr>
<tr>
<td>Comorbid malignancy present</td>
<td>-0.07</td>
<td>0.75</td>
</tr>
<tr>
<td>Comorbid musculoskeletal disease present</td>
<td>-0.06</td>
<td>0.59</td>
</tr>
<tr>
<td>Comorbid cardiovascular disease present</td>
<td>-0.10</td>
<td>0.37</td>
</tr>
<tr>
<td>Comorbid mental disease present</td>
<td>-0.29</td>
<td>0.01*</td>
</tr>
</tbody>
</table>

Additional effects on course of SBP (Panel b):

<table>
<thead>
<tr>
<th>Variable</th>
<th>Effect on SBP (mmHg)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>+2.0</td>
<td>0.11</td>
</tr>
<tr>
<td>Middle SES</td>
<td>-2.5</td>
<td>0.14</td>
</tr>
<tr>
<td>High SES</td>
<td>-0.02</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Low BMI</td>
<td>+3.2</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Young age</td>
<td>+4.0</td>
<td>0.02*</td>
</tr>
<tr>
<td>Comorbid malignancy present</td>
<td>-4.1</td>
<td>0.11</td>
</tr>
<tr>
<td>Comorbid musculoskeletal disease present</td>
<td>-0.3</td>
<td>0.83</td>
</tr>
<tr>
<td>Comorbid cardiovascular disease present</td>
<td>+4.3</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Comorbid mental disease present</td>
<td>-3.5</td>
<td>0.02*</td>
</tr>
</tbody>
</table>

Figure 2. Mixed model results (no subgroup effect analysis): longitudinal HbA1C (a) and SBP (b) outcomes of diabetes patients with and without comorbid COPD. Comorbid diseases: absence and presence are assessed on the date of diabetes diagnosis. Number (n) of cases with complete longitudinal analysis (no missing data on any of the variables included in the mixed model throughout): SB2. Cases with missing values for BMI: n = 23, cases with missing values for SES: n = 5. *P-values < 0.05. Age and BMI categories: based on the distribution of age and BMI values of patients contributing to the analyses, limits for ‘low’, ‘intermediate’ and ‘high’ values were 54, 64 and 72 years for age, and 26.0, 28.5 and 31.8 kg/m2 for BMI, respectively. Graphs for reference categories: in the graphic presentation, graph lines represent HbA1C or SBP courses for specific patient variables—for example, a male patient from the low-SES group with a specific age and BMI. We define the theoretical combination of the patient characteristics ‘male sex, low SES, median age, median BMI and absence of other comorbidity’ as reference category. The ‘Additional effects table’ below each graph contains information needed to construct lines of predicted outcomes, based on the mixed model results, for other subjects than the reference category. It shows the additional effects (to be added to the graphs displayed above) for other covariates included in the model. These values are not time dependent and not dependent on the absence or presence of COPD. Example: HbA1C courses over time for patients with and without comorbid COPD are shown in a. The ‘Additional effects table’ shows an additional effect of +0.04 ( % HbA1C) for female sex. This means 0.04 should be added to the blue line for female patients without COPD and 0.04 should be added to the red line for female patients with COPD. The P-value of 0.70 shows that this additional effect of sex on HbA1C in this analysis is not statistically significant. BMI, body mass index; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; SES, socio-economic status.

DISCUSSION
Main findings
In the current study, we explored the association between comorbid COPD and the longitudinal development of HbA1C and SBP in a representative cohort of newly diagnosed type 2 diabetes patients in primary care during 5 years of follow-up. The initial analyses showed no significant associations between COPD and these outcomes, but subgroup effect analysis indicated that, in the presence of COPD, the development of SBP was different for patients from different SES and BMI subgroups. This suggests that comorbid COPD, in relation with these particular patient characteristics, may influence long-term diabetes control parameters.

Strengths and limitations of this study
In this dynamic cohort study, we used data from robust datasets that originate from decades of experience in morbidity recording in a practice-based research network from our department and good quality of diabetes care.22 We studied relevant diabetes control parameters as study outcomes (not treatment intensification) over a follow-up period that was long enough to assess potential associations with comorbid COPD. Comparison of outcomes over time between patients was meaningful, as we included only newly diagnosed diabetes patients. Another strength is that we studied an unselected population with ‘real patients’ receiving regular primary health care, i.e., a representative sample of the type 2 diabetes patient population.

It is important to realise that, within our study period, the criteria for the diagnosis of COPD and diabetes have changed. The current criteria for diagnosing COPD were introduced in Dutch general practice in 2001.29 Towards the end of our observation period, there was a higher rate of diabetes diagnoses.30 This implies that COPD and diabetes data from early in the observation period may not be fully comparable to similar data at the end of the period. This type of limitation is inherent to working with longitudinal data. In general, the CMR has shown to record diagnoses with high validity.31 One limitation of this study is that we were unable to account for smoking in the analyses, because this has not been consistently recorded in the CMR and NMP databases, nor did we have data available on the severity of COPD (i.e., degree of airflow obstruction, exacerbation rate, severity of dyspnoea). From a previous study, we know that the majority of COPD patients in the NMP registry have mild or moderate COPD,25 but from our current work we cannot tell whether and how the severity of underlying COPD may be associated with the course of diabetes outcomes.

Clearly, the development of HbA1C and SBP over time as observed will have been influenced by the diabetes treatment as provided by GPs. This treatment may include stimulation of physical exercise (which is beneficial not only for the diabetes but also for the COPD) and prescription of glucose-lowering medication.32 Medication prescribed for COPD (e.g., oral or inhaled corticosteroids) may increase the glucose level and SBP in patients with diabetes.13,14 In this dynamic cohort study, it was
It is not possible to compare therapeutic regimes between diabetes patients with and without COPD. Differences in medication or lifestyle regimes may have contributed to the observed differences.

Twenty-eight cases with missing data for SES or BMI throughout the follow-up period (variables included in the linear model) dropped out. Their numbers were relatively low, which makes it unlikely that they introduced bias.

The percentage of diabetes patients with comorbid COPD in our cohort corresponds with prevalence numbers described in the literature. Although the absolute number of patients with COPD (n = 63) was relatively low, one of the subgroup effect analyses did show significant results. In a larger sample of diabetes patients with comorbid COPD, it would have been possible that some nonsignificant trends observed would have reached statistical significance.

The current paper is one result of a larger project with an explorative design aimed at investigating associations between several types of comorbidities on diabetes control parameters. These results generate new hypotheses and may guide further research elaborating on the early findings. It helps increase the evidence base for the complex care to patients with multimorbidity. We believe that the most important strength of the current work is precisely this novelty. To the best of our knowledge, this is the first study exploring longitudinal associations between COPD and another common chronic disease, in this case diabetes. Because the combined occurrence of diabetes and COPD is common, assessing possible interactions in terms of long-term outcomes is important. Our observation that, in some subgroups, comorbid COPD was associated with altered diabetes outcomes warrants further research in this area. Our study may serve as an example of how to investigate the complex relationships between two or more chronic conditions (i.e., multimorbidity) on patients’ prognoses for the diseases involved.

Interpretation of findings in relation to previously published work

The unfavourable effect of increasing BMI on systolic blood pressure is not surprising. Our observations indicate that for diabetes patients with comorbid COPD, patient characteristics that predict long-term outcomes may be different from those without COPD. Our study design had an explorative nature in which we tested several associations; hence, care needs to be taken in the interpretation of our findings. We did not find significant associations between comorbid COPD and all study outcomes tested. It is possible that the significant associations between longitudinal SBP and comorbid COPD among diabetes patients may not be replicated in a future study. It cannot be concluded from observational research only whether and how our findings should be translated into therapeutic consequences. One could reason that, in patients with diabetes and comorbid COPD, factors related to a patient’s SES are more important in achieving long-term SBP control than just reducing BMI. Our finding that among COPD patients the lower SES group had the best long-term SBP...
control is surprising, but this finding would first need to be confirmed in a larger study before we should speculate about possible explanations. In our cohort, diabetes patients with comorbid COPD had different (comorbidity) characteristics than those without COPD—an important notion for the treatment of patients with either or both of these diseases. The observed differences may result from disease-specific or from generic factors such as obesity, lifestyle and smoking. The need for more research aiming at profoundly investigating the associations between COPD, SES and diabetes control parameters is obvious. Previous studies described negative associations between low SES and COPD36 and diabetes19 prognosis. Studies reporting on the relationship between SES and prevalence of multimorbidity in general described negative associations.37–39 We have not been able to trace any previously published papers paying attention to the role of SES in relation to the specific combination of COPD and diabetes.

After the first recognition of the importance of lipid regulation in diabetes,40 the revised version of the Dutch College of General Practitioners diabetes guideline in 1999 resulted in increased attention to the role of lipids halfway through our study period. For this reason, and as studying one glycaemic and one non-glycaemic control parameter already resulted in a large data set with many associations tested, we decided not to include lipids as diabetes control parameters.

Some covariates showed significant additional effects, both on the nonsignificant results from the initial models and on the significant subgroup effect analysis results. Note that these are independent from time and from the presence/absence of COPD. Augmenting effects from increasing BMI and age (on both study outcomes) and from comorbid cardiovascular disease (on SBP) can be expected among diabetes patients. We assume that the consistent diminishing effect of comorbid mental diseases is related to a higher consultation frequency among these patients,41 offering more opportunities to diagnose and manage diabetes (or hypertension) in an early stage, resulting in slightly better outcomes.

Pathophysiologic mechanisms that have been suggested to have a role in the relationship between respiratory impairment in COPD patients and diabetes include an increased BMI, altered respiratory compliance, weakness of the respiratory muscles or neuropahties.7

GPs’ beliefs about the feasibility and benefits of medication regimes may be influenced by the presence of comorbidity,42–44 which might result in deliberate flexible medication prescriptions in patients with comorbidities. Given these considerations, we believe that the absence of an association between comorbid COPD and long-term HbA1C outcomes among diabetes patients implies that GPs responsible for treatment provide good-quality diabetes care despite the presence of comorbidities such as COPD. The majority of practitioners caring for patients with either COPD or diabetes will see several patients with these diseases combined, and our findings may help raise awareness on the importance of formulating personalised management plans that aim for sensible outcomes taking into account both diseases. The current explorations do not yet allow for concrete recommendations for daily practice changes—our findings need to be replicated in larger diabetes cohorts.

Knowledge of the impact of comorbidity on disease outcomes is also important to support pay-for-performance initiatives that facilitate patient-centred care. Therefore, ongoing research in this area should be prioritised by funding bodies and policymakers.

Conclusions

Comorbid COPD was associated with longitudinal control parameters of newly diagnosed type 2 diabetes patients in general practice. This association was observed on SBP (but not on HbA1C) and was modified by SES and BMI. Although these results need to be verified first, this exploratory study provides new information on the interaction between multiple chronic diseases, and may guide further development of personalised care that accounts for patients’ comorbidity.

ACKNOWLEDGEMENTS

We thank all GPs and practice assistants in the CMR-NMP practices for their years of consistent morbidity and outcome recording.

CONTRIBUTIONS

TS is an Associate editor of npj Primary Care Respiratory Medicine, but was not involved in the editorial review of, nor the decision to publish, this article. HL and TS conceived and designed the study, with contributions from WdG, MB, JB, AL-J and CvW. HL and JB acquired the data. HL and TS drafted the manuscript and WdG, MB, CvW, AL-J and JB critically revised it. Statistical analysis was performed by HL and HB, with contributions from TS, WdG and MB. WdG, CvW and AL-J supervised the study. JB is a statistician. HL is the guarantor of the study. The other authors declare no conflict of interest.

COMPETING INTERESTS

The authors declare no conflict of interest.

FUNDING

There was no specific funding for the current work. Hilde Luijks received a personal research development grant to combine her general practice specialty training with a research training, from SBOH, employer of general practitioner trainees in the Netherlands.

REFERENCES
